Faculty, Staff and Student Publications
Publication Date
6-1-2023
Journal
The Journal for ImmunoTherapy of Cancer
Abstract
Advanced gynecologic cancers have historically lacked effective treatment options. Recently, immune checkpoint inhibitors (ICIs) have been approved by the US Food and Drug Administration for the treatment of cervical cancer and endometrial cancer, offering durable responses for some patients. In addition, many immunotherapy strategies are under investigation for the treatment of earlier stages of disease or in other gynecologic cancers, such as ovarian cancer and rare gynecologic tumors. While the integration of ICIs into the standard of care has improved outcomes for patients, their use requires a nuanced understanding of biomarker testing, treatment selection, patient selection, response evaluation and surveillance, and patient quality of life considerations, among other topics. To address this need for guidance, the Society for Immunotherapy of Cancer (SITC) convened a multidisciplinary panel of experts to develop a clinical practice guideline. The Expert Panel drew on the published literature as well as their own clinical experience to develop evidence- and consensus-based recommendations to provide guidance to cancer care professionals treating patients with gynecologic cancer.
Keywords
Female, Humans, Genital Neoplasms, Female, Immunotherapy, Quality of Life, Treatment Outcome, Uterine Cervical Neoplasms
DOI
10.1136/jitc-2022-006624
PMID
37295818
PMCID
PMC10277149
PubMedCentral® Posted Date
6-9-2023
PubMedCentral® Full Text Version
Post-print
Correction
Published Open-Access
yes
Included in
Bioinformatics Commons, Biomedical Informatics Commons, Genetic Phenomena Commons, Immunotherapy Commons, Medical Genetics Commons, Oncology Commons
Comments
This article has been corrected. See J Immunother Cancer. 2023 Jun 26;11(6):1.